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ABSTRACT
Given that parthenolide (PTL) is an effective antileukemic agent,
identifying molecular markers that predict response to PTL is
important. We evaluated the role of myeloperoxidase (MPO) in
determining the sensitivity of leukemia cells to PTL-induced
apoptosis. In this study, the level of PTL-induced generation of
reactive oxygen species (ROS) and apoptosis was significantly
higher in the MPO-high leukemia cell lines compared with the
MPO-low leukemia cell lines. Pretreatment of MPO-high leuke-
mia cells with a MPO-specific inhibitor, 4-aminobenzoic acid
hydrazide, or a MPO-specific small interfering RNA (siRNA)
abrogated the PTL-induced ROS generation and apoptosis,
indicating that MPO plays a crucial role in PTL-induced
apoptosis in leukemia cells. PTL-induced apoptosis was ac-
companied by down-regulation of nuclear factor-B, Bcl-xL,
Mcl-1, X-linked inhibitor of apoptosis protein, and survivin and
selectively observed in primary acute myeloid leukemia (AML)
cells expressing higher levels of MPO (50%) while sparing
both AML cells with lower MPO and normal CD34-positive
(CD34) normal bone marrow cells. The extent of PTL-induced
apoptosis of the CD34CD38 cell fraction was significantly
greater in the MPO-high AML cases, compared with the MPO-
low AML (P 0.01) and normal CD34marrow cells (P 0.01).
Nonobese diabetic/severe combined immunodeficient human
leukemia mouse model also revealed that PTL preferentially
targets the MPO-high AML cells. Our data suggest that MPO
plays a crucial role in determining the susceptibility of leukemia
cells to PTL-induced apoptosis. PTL can be considered a
promising leukemic stem cell-targeted therapy for AML ex-
pressing high levels of MPO.
Introduction
Parthenolide (PTL) is a sesquiterpene lactone and the
active component of the medicinal plant feverfew (Tanac-
etum parthenium) (Knight, 1995). PTL contains both an
-methylene--lactone ring and an epoxide group, which
interact with the nucleophilic sites of many biological mol-
ecules (Bork et al., 1997). In addition to its well known
antimicrobial and anti-inflammatory properties (Brown et
al., 1997), PTL has been reported to inhibit cell growth and
induce apoptosis in a variety of tumor cells (Wiedhopf et
al., 1973; Woynarowski and Konopa, 1981; Ross et al.,
1999; Zhang et al., 2004b). It is noteworthy that PTL has
also been shown to effectively eradicate acute myeloid
leukemia (AML) stem cells and progenitor cells in vitro
while sparing normal hematopoietic stem cells (Guzman et
al., 2005). Thus, PTL could be an attractive agent for
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treating myeloid leukemia bulk and leukemia stem cells
(LSC).
Several mechanisms have been shown to be involved in the
antitumor effect of PTL, including the inhibition of nucleic
acid synthesis (Woynarowski and Konopa, 1981), induction of
mitochondrial dysfunction (Wen et al., 2002), disruption of
intracellular calcium equilibrium (Zhang et al., 2004b), in-
duction of G2-M phase arrest (Wen et al., 2002; Pozarowski et
al., 2003), and sustained activation of c-Jun N-terminal ki-
nase (JNK) (Nakshatri et al., 2004; Zhang et al., 2004a). In
addition, PTL blocks signal transduction and the activators
of transcription 3 (STAT3) phosphorylation (Sobota et al.,
2000). PTL is a potent inhibitor of NF-B activation through
direct binding to IB-kinase (IKK) (Hehner et al., 1999;
Kwok et al., 2001; Zhang et al., 2004a). Most importantly,
PTL induces cell death through the generation of intracellu-
lar reactive oxygen species (ROS) in a glutathione-sensitive
manner (Wen et al., 2002; Zhang et al., 2004b; Guzman et al.,
2005). Because malignant cells are highly susceptible to PTL-
induced cell death (Wang et al., 2006), it is important to
identify specific markers that indicate the susceptibility of
leukemic cells to PTL-induced cell death to allow the effec-
tiveness of PTL as an antileukemia agent to be predicted.
Myeloperoxidase (MPO), a heme protein abundantly ex-
pressed in azurophilic granules (Eiserich et al., 2002), cata-
lyzes the formation of hypochlorous acid, a potent oxidant
implicated in killing bacteria (Bryk et al., 2002). The MPO
tissue destruction occurs through induction of necrosis and
apoptosis (Wagner et al., 2000; Klebanoff, 2005). Expression
of the MPO molecule is specific for myeloid precursors and
their leukemic counterparts. Evidence of the functional sig-
nificance of the MPO molecule, in addition to its diagnostic
importance, in myeloid leukemia cells is accumulating. The
percentage of MPO-positive blast cells is highly associated
with clinical outcomes of AML (Takubo et al., 1983; Matsuo
et al., 2003). The Japan Adult Leukemia Study Group study
demonstrated that AML patients with 50% or higher MPO-
positive blast cells have a significantly better outcome (Mat-
suo et al., 2003), although the biological significance of the
MPO molecule as a prognosis-determining factor in AML is
unknown. Recently, it has been shown that MPO is a key
regulator of oxidative stress-mediated apoptosis in myeloid
leukemia cells (Nakazato et al., 2007). ROS is the direct
mediator of green tea polyphenol ()-epigallocatechin-3-gal-
late (EGCG)-induced apoptosis in MPO-positive leukemia
cells, whereas EGCG fails to induce apoptosis in MPO-nega-
tive leukemia cells (Nakazato et al., 2007). Therefore, MPO
may be an important determinant of myeloid leukemia cell
sensitivity to oxidative stress-mediated apoptosis induced by
several antileukemia agents.
The aim of this study is to evaluate whether MPO plays a
critical role in PTL-induced apoptosis of leukemia cells.
Therefore, the detailed molecular mechanism of PTL-induced
apoptosis in relation to MPO expression was further investi-
gated. It is noteworthy that the high susceptibility of leuke-
mia cells to PTL-induced apoptosis is selectively documented
in primary AML bulk cells, as well as CD34CD38 AML
LSC candidates expressing high levels of MPO. In contrast,
PTL at a concentration that induces a substantial degree of
apoptosis in the MPO-highly expressing leukemia cells does
not affect survival of CD34-positive normal hematopoietic
stem cells. According to our findings, MPO expression is a
critical determinant of PTL-induced apoptosis in leukemia
cells. Thus, PTL can be considered as a promising LSC-
targeted therapy for AML with a high level of MPO.
Materials and Methods
Cells, Reagents, and Culture. U937, K562, HL60, Kasumi-1,
NB4, KG1, OCI-AML3, and MOLM13 human leukemia cell lines
(American Type Culture Collection, Manassas, VA) were maintained
in RPMI 1640 medium supplemented with 25 mM L-glutamine
(Cambrex BioScience, Walkersville, MD) and 10% (v/v) heat-inacti-
vated fetal bovine serum (FBS; HyClone Laboratories, Logan, UT).
Primary leukemic cells were isolated in bone marrow samples of
untreated patients with AML. The isolation of CD34-positive cells
from normal bone marrow was performed using the immunomag-
netic microbead method (Kim et al., 2007). Specimens were collected
under the Severance Hospital Institutional Review Board-approved
clinical sample procurement protocols, and informed consent was
obtained in accordance with the Declaration of Helsinki. Parthenol-
ide [4xi-Germacra-1(10),11(13)-dien-12-oic acid, 4,5-epoxy-6.alpha.-
hydroxy-, -lactone/C15H20O3, Calbiochem, San Diego, CA] was re-
constituted in dimethyl sulfoxide (DMSO) to a stock concentration of
50 mM. Cells were resuspended at a density of 2  105/ml in a
medium containing 10% FBS and incubated at 37°C in the presence
of various concentrations of PTL for the indicated times, which were
then harvested for subsequent analyses. Control cells were treated
with equal amounts of the solvent. The caspase inhibitor z-VAD-
fmk [benzyloxycarbonyl-Val-Ala-Asp (OMe) fluoromethylketone],
an MPO inhibitor 4-aminobenzoic acid hydrazide (ABAH), and a
p38 inhibitor, SB203580 (4-[4-(4-fluorophenyl)-2-(4-methylsulfinyl-
phenyl)-1H-imidazol-5-yl]pyridine), were purchased from Calbio-
chem. A heme biosynthesis inhibitor succinylacetone (ScAc) and
JNK inhibitor SP600125 (anthra[1,9-cd]pyrazol-6(2H)-one) were ob-
tained from Sigma-Aldrich (St. Louis, MO) and Biomol (Plymouth
Meeting, PA), respectively. All experiments were performed in
triplicate.
Antibodies. Rabbit anti-MPO polyclonal and mouse anti--tubu-
lin monoclonal antibodies were obtained from Upstate Biotechnology
(Lake Placid, NY). Rabbit polyclonal antibodies against poly(ADP)ri-
bose polymerase (PARP), XIAP, BID, tBID, Bak, PUMA, JNK, phos-
pho(p)-JNK, p38, p-p38, survivin, as well as horseradish peroxidase
(HRP)-conjugated goat anti-rabbit IgG and HRP-conjugated goat
anti-mouse IgG, were purchased from Cell Signaling Technology
(Beverly, MA). Rabbit polyclonal antibodies against NF-B (p65),
Mcl-1, and Bcl-xL were obtained from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA). The mouse monoclonal antibodies against
caspase-8, capase-9, cytochrome c, and Smac/DIABLO, and rabbit
polyclonal antibody against caspase-3 were obtained from Phar-
Mingen (San Diego, CA). To analyze human cell engraftment in the
nonobese diabetic/severe combined immunodeficient (NOD/SCID)
experiments, bone marrow cells were blocked with the anti-Fc recep-
tor antibody 2.4G2 and labeled with antihuman CD45 and CD33
antibodies (BD Biosciences, San Jose, CA).
Evaluation of MPO Expression. MPO expression was evalu-
ated using flow cytometry. For fixation and permeabilization of the
cells, an Intraprep cell permeabilization kit (Beckman Coulter, Ful-
lerton, CA) was used. The cells (5  105) were incubated for 30 min
at room temperature with an anti-MPO antibody (Abcam, Cam-
bridge, UK), and an isotype-matched mouse IgG served as the con-
trol. The cells were washed in cold DPBS at 4°C and resuspended in
5 	l of FITC-labeled goat anti-mouse IgG antibody (PharMingen) for
15 min. To analyze MPO expression in CD34CD38 AML cells,
cells were labeled with anti-CD34-phycoerythrin (PE; BD Bio-
sciences), anti-CD38-PerCP-Cy5.5 (PharMingen), and anti-MPO an-
tibody for 30 min. The cells were washed in cold DPBS at 4°C
(Dulbecco’s phosphate-buffered saline) and resuspended in 5 	l of
FITC-labeled goat anti-mouse IgG antibody. Flow cytometric analy-
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sis was conducted using a FACSCalibur flow cytometer (Becton
Dickinson Immunocytometry Systems, BDIS, San Jose, CA). The
percentage of cells expressing MPO was defined on the gates set for
the CD34CD38 population.
Measurement of MPO Activity. Cells were harvested, washed
with DPBS, and then homogenized in a phosphate buffer containing
1% hexadecyltrimethylammonium hydroxide and centrifuged at
4500g for 15 min at 4°C to assay for MPO in the supernatants. MPO
activity was measured using an enzyme immunometric assay kit for
human MPO (Assay Designs, Ann Arbor, MI).
Stable Transfection of K562 Cells withWild-Type orMutant
MPO cDNA. For transfection of wild-type or mutant MPO cDNA
to K562 cells, the nucleofection method was used (Kim et al.,
2007). A transfection mixture was prepared by mixing 5 	g of
DNA with 100 	l of human Nucleofector V solution (Amaxa Bio-
systems, Gaithersburg, MD). pCI-MPO wild-type and pCI-MPO/
R569W mutant cDNAs were kindly provided by Dr. Yasushi
Miyazaki (Nagasaki University, Nagasaki City, Japan), with the
pCI empty vector used as a control. The cell suspension (2  106
cells/ml) was immediately electroporated using a Nucleofector
instrument (program T-16; Amaxa Biosystems). After electropo-
ration, cells were immediately cultured with a complete medium
in six-well plates in a 37°C/5% CO2 incubator. Stable transfec-
tants (K562/control, K562/MPO, and K562/R569W) were selected
as a single clone in the presence of 1 mg/ml G418 (Sigma-
Aldrich).
Transient Transfection of MPO siRNA. MPO-specific small
interfering RNA (siRNA) (5-AGGCATCACCACCGTGTCTAA-3)
was purchased from QIAGEN, Inc. (Valencia, CA). The cell suspen-
sion of 2  106 leukemia cells was immediately transfected with
MPO-specific siRNA using the Nucleofector instrument (Amaxa Bio-
systems) in accordance with the manufacturer’s instructions. Imme-
diately after electroporation, the cells were resuspended in a com-
plete medium and incubated in a humidified 37°C/5% CO2 incubator.
Mock control siRNA transfection was also performed for control
experiments. The cells were harvested after 24 h and used in subse-
quent experiments.
Apoptosis Assay. The annexin V assay was performed as de-
scribed (Kim et al., 2007). Cultured cells were washed and incubated
in 100 	l of binding buffer containing 5 	l of annexin V-FITC
(PharMingen). The nuclei were counterstained with propidium io-
dide (PI), and the fraction of apoptotic cells was determined by flow
cytometry. To identify apoptotic CD34CD38 cells, cells were la-
beled with anti-CD34-PE-Texas Red (ECD; Beckman Coulter) and
anti-CD38-PE (BD Biosciences) for 30 min. The labeled cells were
subsequently resuspended in 100 	l of annexin V-binding buffer and
incubated with annexin V-FITC and 7-aminoactinomycin (7-AAD;
Beckman Coulter) for 20 min at room temperature before analysis by
flow cytometry.
Assessment of Loss of Mitochondrial Membrane Potential.
The loss of mitochondrial membrane potential (MMP) was monitored
using DiOC6 (Kim et al., 2007). For each condition, 4 10
5 cells were
incubated at 37°C for 15 min in 1 ml of 40 nM DiOC6 (Calbiochem)
and subsequently analyzed by flow cytometry. The control experi-
ments documenting the loss of MMP were performed by exposing the
cells to 5 	M carbamoyl cyanide m-chlorophenylhydrazone (Sigma-
Aldrich), an uncoupling agent that abolishes MMP.
Cell-Cycle Analysis. Cells were fixed in 70% ethanol at 20°C
for 16 h and resuspended in 1 ml of cell cycle buffer (0.38 mM/l
sodium citrate, 0.5 mg/ml RNase A, 0.01 mg/ml PI) at a concentra-
tion of 1  106 cells/ml. Cell-cycle analysis was carried out using a
FACSCalibur flow cytometer equipped with ModFit LT 3.0 software
(Verity Software House, Topsham, ME).
Measurement of Intracellular Generation of ROS. To assess
the intracellular production of ROS, cells were treated with PTL
alone or together with the antioxidant N-acetylcysteine [NAC;
(R)-2-acetamido-3-sulfanylpropanoic acid; Sigma-Aldrich]. After
the treatment, the cells were incubated with 10 	M/l dichlorodi-
hydrofluorescein diacetate (DCFH-DA; Invitrogen, Carlsbad, CA),
which is oxidized by cellular ROS and forms the fluorescent com-
pound dihydrofluorescein. In addition, 1  105 cells were stained
with 10 	M/l DCFH-DA for 30 min at 37°C and then washed and
resuspended in DPBS. The oxidative conversion of DCFH-DA to
dihydrofluorescein was measured by flow cytometry.
Measurement of Intracellular GSH Content. Changes in total
cellular glutathione (GSH) levels were determined using a glutathi-
one assay kit (Sigma-Aldrich), in accordance with the manufacturer’s
instructions. PTL-treated cells were harvested and lysed with a
1 lysis solution. Supernatant was added to each well of a 96-well
plate, followed by the addition of 5 	l of glutathione S-transferase
(GST), 2.5 	l of substrate solution, and assay buffer. After thor-
ough mixing and incubation at 37°C for 60 min, fluorescence
emissions at 478 nm were determined with a luminescence spec-
trometer (PerkinElmer Life and Analytical Sciences, Waltham,
MA) after excitation at 390 nm.
Western Blot Analysis. After the cells were lysed in lysis buffer
(50 mM Tris-HCl, pH 7.5, 120 mM NaCl, 20 mM NaF, 1 mM EDTA,
5 mM EGTA, 15 mM sodium pyrophosphate, 1 mM benzamidine, 0.1
mM phenylmethylsulfonyl fluoride, and 1% Nonidet P-40) and
briefly sonicated, mitochondrial and cytosolic fractionation were per-
formed using a cytosolic/mitochondria fractionation kit (Oncogene
Research Products, San Diego, CA). Protein yields were quantified
using the Bio-Rad detergent-compatible protein assay kit (Bio-Rad,
Hercules, CA). Equivalent amounts of protein (20 	g) were boiled for
10 min and resolved on a 15% polyacrylamide gel by SDS-polyacryl-
amide gel electrophoresis. The proteins were subsequently trans-
ferred onto nitrocellulose membranes (GE Healthcare, Little Chal-
font, Buckinghamshire, UK), which were washed and incubated with
the primary antibody for 2 h at room temperature. After washing,
the membranes were incubated with the relevant HRP-conjugated
secondary antibody (1:3000 diluted in Tris-buffered saline/Tween 20
containing 5% bovine serum albumin) for 1 h. After the membrane
was washed four times in Tris-buffered saline/Tween 20, the reactive
proteins were visualized using an enhanced chemiluminescence de-
tection system (GE Healthcare).
NOD/SCID Human Leukemia Mice Model Assay. NOD/SCID
(NOD.CB17-prdkdc scid/J) mice (Jackson Laboratories, Bar Harbor,
ME) were irradiated with 2.7 Gy using a RadSource X-ray irradiator
(RadSource, Boca Raton, FL) 1 day before transplantation. Human
leukemia cells to be assayed were injected using the tail vein (5–10
106 cells) in a final volume of 0.2 ml of phosphate-buffered saline
containing 0.5% FBS. After 6 to 8 weeks, the animals were sacrificed,
and their bone marrow was analyzed for the presence of human cells
by flow cytometry.
Statistical Analysis. Primary AML cases were divided into two
groups based on the expression level of MPO protein in the leukemia
cells: MPO-low and MPO-high. We arbitrarily defined primary AML
cases as MPO-high and MPO-low AML according to whether the
fraction of leukemic blasts expressing MPO was greater and lesser
than 50% of the total mononuclear cells, respectively. The compari-
sons among the characteristics between groups were made using the

2 test for binary variables and the Mann-Whitney test for continu-
ous variables. The statistics were calculated using SPSS software,
version 11.0.1 (SPSS, Inc., Chicago, IL), with P  0.05 considered as
significant.
Results
MPO Expression and Activity in Leukemia Cells.
MPO expression was examined in several leukemia cell lines
using flow cytometric analysis. Whereas MPO expression
was observed to be low in the K562, U937, KG1, and OCI-
AML3 cell lines, MPO was highly expressed in the HL60,
NB4, Kasumi, and MOLM13 cell lines (Fig. 1A, top). This
was confirmed by Western blot analysis as the heavy ()-
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subunit of mature MPO was observed in the HL60, NB4,
Kasumi and MOLM13 cell lines but not in the K562, U937,
KG1, and OCI-AML3 cell lines (Fig. 1A, bottom). In addition,
as shown in Fig. 1B, MPO activity was remarkably higher in
the HL60, NB4, and Kasumi cell lines compared with both of
the K562 and U937 cell lines.
PTL-Induced Apoptosis According to MPO Expres-
sion. Apoptosis of leukemia cells induced by various con-
centrations of PTL was measured. The sensitivity of leu-
kemia cell lines to PTL-induced apoptosis was highly
dependent on the level of constitutive MPO expression. A
limited degree of apoptosis was observed in U937 (9.7 
Fig. 1. Differential sensitivity of leuke-
mia cell lines to PTL-induced apoptosis
according to MPO expression. A, consti-
tutive expression of MPO protein in leu-
kemia cell lines was examined by flow
cytometry (top) and Western blot analysis
(bottom) using the appropriate antibodies.
B, MPO activity of the leukemia cell lines
was measured using a human MPO en-
zyme immunometric assay as described un-
der Materials and Methods. C, MPO-low
cell lines (K562, U937, KG1, OCI-
AML3) and MPO-high cell lines (HL60,
NB4, Kasumi-1, MOLM13) were ex-
posed to the indicated concentration of
PTL for 24 h, and then the percentage of
apoptotic cells was determined by an-
nexin-V/PI staining using flow cytom-
etry (left). Cells were cultured with 10
	M PTL for 24 h, fixed with 70% Et-OH,
and stained with PI, after which the
percentage of sub-G1 populations was
determined by flow cytometry (right).
D, after treatment with 10 	M PTL for
24 h, the disruption of MMP was mea-
sured by DiOC6 incubation and flow cy-
tometry analysis in U937 and NB4 cells
as described under Materials and Meth-
ods (top). Cytoplasmic translocation of
cytochrome c and Smac/DIABLO pro-
tein was evaluated by Western blot
analysis of the cytoplasmic and mito-
chondrial fraction (bottom). E, cleavage
of caspases-8, -9, -3, and PARP was ex-
amined in U937 and HL60 cells 24 h
after PTL treatment using Western blot
analysis (bottom). The cells were ex-
posed to 10 	M PTL for 24 h in the
presence or absence of caspase inhibitor
z-VAD-fmk (20 	M), after which the
percentage of annexin V-positive apop-
totic cells was determined by flow cy-
tometry (bottom). Note that -tubulin
served as a loading control. Columns,
mean value of three independent exper-
iments; bars, S.D. Cyto, cytoplasmic
fraction; Mito, mitochondrial fraction. ,
P  0.05; , P  0.01; , P  0.001;
NS, not significant.
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0.2%), K562 (11.0  0.1%), KG1 (6.2  1.1%), and OCI-
AML3 (1.8  0.1%) after 24 h of treatment with 10 	M PTL
(Fig. 1C). However, the proportion of apoptotic cells in the
HL60, NB4, Kasumi, and MOLM13 cell lines was mark-
edly increased in a dose-dependent manner with PTL
treatment. After 24 h of treatment with 10 	M PTL, the
mean proportion of apoptotic cells was 92.5  0.7% in
HL60, 81.5  1.1% in NB4, 89.2  0.8% in Kasumi, and
73.2  1.9% in MOLM13 cell lines, which was remarkably
higher than in the K562, U937, KG1, and OCI-AML3 cells
(HL60 versus U937 or K562 or KG1 or OCI-AML3, P 
0.001; NB4 versus U937 or K562 or KG1 or OCI-AML3,
P  0.001; Kasumi versus U937 or K562 or KG1 or OCI-
AML3, p  0.001; MOLM13 versus U937 or K562 or KG1
or OCI-AML3, P  0.001; Fig. 1C, left). These findings
indicate that leukemia cells that express higher MPO lev-
els are more sensitive to PTL-induced cell death. Signifi-
cant increases in the proportion of leukemia cells in the
sub-G1 fraction after PTL treatment were limited to the
high MPO-expressing cell lines (Fig. 1C, right).
The extent of MMP disruption induced by PTL was as-
sessed by measuring the mitochondrial-mediated uptake of a
membrane potential-sensitive dye DiOC6. The loss of MMP
was significantly greater in HL60 cells compared with U937
cells (Fig. 1D, top), suggesting that mitochondrial-mediated
apoptotic cell death induced by PTL occurred preferentially
in leukemia cells that express higher level of MPO. PTL-
induced cytoplasmic translocation of cytochrome c and Smac/
DIABLO (Fig. 1D, bottom) and the cleavage of caspases-3, -8,
-9, and PARP (Fig. 1E, top) were also limited to HL60 cells. In
contrast, cytoplasmic translocation of cytochrome c and
Smac/DIABLO and cleavage of caspase cascades in U937
cells did not occur after PTL treatment. Pretreatment of
HL60 cells with 20 	M of a pan-caspase inhibitor, z-VAD-
fmk, led to the abrogation of PTL-induced cell death (Fig. 1E,
bottom). These results indicate an association between ex-
pression of MPO and susceptibility to PTL-induced apopto-
sis, with this mechanism caspase-dependent.
PTL-Induced ROS Generation in Relation to MPO
Expression. To explore whether MPO is critically involved
in PTL-induced oxidative damage in leukemia cells, PTL-
induced generation of intracellular ROS was measured in
various leukemia cell lines. Five hours after treatment with
10 	M PTL, flow cytometric analysis showed that the mean
relative ROS levels in the MPO-high HL60, NB4, and Ka-
sumi cells were remarkably higher than those in the MPO-
low K562 and U937 cells (Fig. 2A, left). This finding suggests
that MPO-high cells produce more ROS than MPO-low cells
with PTL treatment.
When leukemia cells were preincubated with 1 mM of the
free radical scavenger L-N-acetylcysteine (L-NAC) 1 h before
PTL treatment ROS generation (Fig. 2A, right) and apoptosis
(Fig. 2B) were almost completely abrogated in HL60, NB4,
and Kasumi cells. This abrogation clearly suggests that an
elevated ROS is crucial for PTL-induced apoptosis in MPO-
high leukemia cells. We also measured the alteration of GSH
levels upon PTL treatment; significant GSH depletion was
observed only in HL60, NB4, and Kasumi cells (Fig. 2C). In
addition, L-NAC pretreatment of the MPO-high cell lines
completely abrogates the PTL-induced GSH depletion, which
did not occur in the MPO-low cell lines (Fig. 2C).
To elucidate the role of MPO in ROS-mediated apoptosis
that is induced by PTL, we evaluated the effect of the MPO-
specific inhibitor ABAH and the heme biosynthesis inhibitor
ScAc on PTL-induced apoptosis by flow cytometric analysis
(Fig. 2D, left). Preincubation of NB4 cells with 100 	MABAH
or 0.5 mM ScAc resulted in a significant inhibition of PTL-
induced cell death (Fig. 2D, right). We further evaluated the
effects of MPO-specific siRNA-mediated knockdown of MPO
expression on the PTL-induced cell death. Western blot anal-
ysis demonstrated that MPO expression was effectively
down-regulated in NB4 cells 24 h after transfection of cells
with a MPO-specific siRNA, as described under Materials
and Methods (Fig. 2E, top). MPO silencing significantly de-
creased the level of PTL-induced apoptosis in NB4 cells in a
dose-dependent manner, whereas it was not observed in the
control siRNA-transfected NB4 cells (Fig. 2E, bottom). Dis-
cernible effects were not seen in U937 cells. These findings
clearly indicate that MPO activity plays a crucial role in
PTL-induced cell death in leukemia cells.
PTL-Induced Changes in the Apoptosis-Regulating
Molecules According to MPO Expression. Alterations in
the levels of various antiapoptotic and proapoptotic mole-
cules were evaluated after PTL treatment in leukemia cells.
MPO-high HL60 cells showed a marked decrease in the levels
of NF-B (p65), Bcl-xL, Mcl-1, XIAP, and survivin after 10
	M PTL treatment for 24 h (Fig. 3A). In contrast, these
antiapoptotic molecules were not affected by PTL in MPO-
low U937 cells. BID cleavage, Bak induction, and the pres-
ence of PUMA were observed only in HL60 cells with PTL
treatment (Fig. 3A). A greater extent of phosphorylation JNK
(p-JNK) was also observed in HL60 cells (Fig. 3B, top). How-
ever, p38 MAPK and phospho-p38 MAPK were not altered in
either U937 or HL60 cells. Preincubation of HL60 cells with
10 	M JNK-specific inhibitor SP600125 for 3 h abrogated
PTL-induced cell death (Fig. 3B, bottom), suggesting that
PTL-induced cell death in HL60 cells occurs through the JNK
pathway. However, pretreatment of HL60 or U937 cells with
the p38-specific inhibitor SB203580 did not affect PTL-in-
duced cell death (Fig. 3B, bottom).
Induced Overexpression of Wild-Type MPO-Enhances
PTL-Induced Apoptosis. To determine whether MPO ex-
pression directly contributes to the sensitivity of leukemia
cells to PTL-induced apoptosis, two stable transfected cell
lines that overexpress wild-type MPO (K562/MPO) or mu-
tant MPO (K562/R569W) were used. K562 cells transfected
with a pCI empty vector were used as a control. As shown by
the flow cytometric and Western blot analysis, the heavy ()
subunit MPO protein was highly expressed in K562/MPO cell
line, although not in the parental K562, K562/control, or
K562/R569W cell lines (Fig. 4A).
The percentage of apoptotic cells in K562/MPO cells
(65.8  7.6%) 24 h after treatment with 10 	M PTL was
found to be significantly higher compared with parental
K562 (5.7  1.2%, p  0.05), K562/control (6.1  1.3%, p 
0.05), and K562/R569W cells (11.4  2.8%, p  0.05) (Fig.
4b1). The histograms show a greater extent of sub-G1 popu-
lations in K562/MPO cells after PTL treatment (Fig. 4b2,
left). The proportion of cells at the sub-G1 phase was also
significantly higher in K562/MPO (58.9  0.1%) compared
with K562 cells (3.5  0.7%, p  0.01; Fig. 4b2, right). The
loss of MMP observed 24 h after PTL treatment was also sig-
nificantly higher in K562/MPO cells (45.0 8.7%) than in K562
cells (0.7  0.1%, p  0.05, Fig. 4b3, left). PTL-induced cyto-
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plasmic translocation of cytochrome c and Smac/DAIBLO was
observed only in K562/MPO cells (Fig. 4b3, right). Caspase-
dependent apoptosis, which was abolished with 20 	M z-VAD-
fmk pretreatment before PTL addition, was confined to K562/
MPO cells (Fig. 4b4). These findings suggest thatMPO plays an
important role in determining the sensitivity of myeloid leuke-
mia cells to PTL-induced apoptosis through a mitochondria-
mediated, caspase-dependent manner.
Pretreatment of K562/MPO cells with L-NAC pretreatment
completely inhibited the PTL-induced ROS generation, indi-
cating that elevated ROS is crucial for PTL-induced apopto-
sis in K562/MPO cells (Fig. 4C, top). PTL-induced ROS gen-
eration was also significantly higher in the K562/MPO cells
(31.5 1.0%) compared with parental K562 cells (2.4 0.3%,
P  0.01) (Fig. 4C, bottom). Likewise, MPO overexpression
contributed to PTL-induced GSH depletion. GSH depletion
was significantly greater in the K562/MPO cells compared
with K562 cells (P  0.001, Fig. 4D). In contrast to the
Fig. 2. PTL-induced ROS generation with
depletion of GSH in relation to MPO ex-
pression. A, MPO-low cell lines (K562,
U937) and MPO-high cell lines (HL60,
NB4, Kasumi-1) were treated with 10 	M
PTL for 5 h in the presence or absence of
prior treatment with 1 mM antioxidant
NAC for 1 h. After incubation, intracellular
ROS generation was measured using flow
cytometric analysis as described underMa-
terials and Methods. The representative
histograms (left) and bar graphs (right)
show a greater extent of ROS generation in
MPO-high leukemia cell lines. Cells were
treated with 10 	M PTL for 24 h with or
without NAC pretreatment, and then the
fraction of apoptotic cells (B) and the intra-
cellular GSH depletion (C) was evaluated
using flow cytometry and luminescence
spectrometer, respectively. D, U937 and
NB4 cells were treated with PTL for 24 h in
the absence or presence of ABAH (100 	M,
24 h) or ScAc (0.5 mM, 3 h) pretreatment,
and then the percentage of apoptotic cells
was determined by flow cytometric analy-
sis (left and right). E, U937 and NB4 cells
were transfected with specific-MPO siRNA
as described underMaterials andMethods.
Mock siRNA transfection was conducted as
control experiment. After MPO gene silenc-
ing for 24 h, total cell lysates of U937 and
NB4 cells were analyzed by Western blot-
ting using antibody against MPO. MPO/-
tubulin ratio according to amount of MPO
siRNA was shown below the blots (top).
The cells were treated with PTL for 24 h in
the absence or presence of specific-MPO
siRNA, and then the percentage of apopto-
tic cells was determined by flow cytometric
analysis (bottom). Columns, mean of three
independent experiments; Bars, S.D. , P
0.05; , P  0.01; , P  0.001.
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parental K562 cells, treatment of K562/MPO cells with PTL
for 24 h resulted in a marked decrease in the level of NF-B,
Bcl-xL, Mcl-1, XIAP, and survivin, indicating that MPO ex-
pression is directly associated with PTL-induced down-regu-
lation of several antiapoptotic molecules (Fig. 4E). JNK phos-
phorylation was also more prominent in K562/MPO.
Differential Sensitivity of Primary AML Cells to PTL
According to MPO Expression. We examined primary
leukemic blasts obtained from patients with de novo AML
and evaluated the correlation between the extent of PTL-
induced cell death and their MPO expression levels (Table 1).
Although MPO is an enzyme that is associated with myeloid
lineage leukemia, variations in the proportion of MPO-posi-
tive leukemia cells were observed among the cases. As de-
scribed in “Statistical Analysis,” primary AML cases were
arbitrarily defined as the MPO-high and MPO-low AML ac-
cording to whether the fraction of leukemic blasts expressing
MPO was greater or less than 50% of the total mononuclear
cells. It was found that MPO activity was significantly higher
in cases classified as MPO-high AML compared with MPO-
low AML (P  0.01) and normal CD34 bone marrow cells
(P 0.01) (Fig. 5A). The average percentage of apoptotic cells
induced by PTL treatment was also significantly higher in
MPO-high AML cases (44.4  0.6%, n  6) compared with
MPO-low AML cases (1.4  0.7%, n  4, P  0.001) and
normal bone marrow CD34 cells (8.8  0.5%, n  4, P 
0.001) (Fig. 5B). The representative histograms show a
greater extent of ROS production in MPO-high AML cells
(Fig. 5C, top). PTL-induced increase in the relative ROS
levels was also significantly higher in the MPO-high AML
(24.4  1.6%) compared with MPO-low AML cases (5.9 
0.3%, P  0.001) and normal bone marrow CD34 cells
(5.6  0.6%, P  0.001, Fig. 5C, bottom). In addition, a
significant level of GSH depletion was observed only in MPO-
high AML (Fig. 5D). As a whole, these findings suggest that
PTL is a potent antileukemic agent that potentially induces
ROS generation and apoptosis in primary MPO-high AML
cells while sparing normal hematopoietic stem cells and
MPO-low AML cells.
MPO Expression and PTL-Induced Apoptosis in
CD34CD38 LSC. MPO expression in potential LSC
candidate CD34CD38 leukemic blasts from 14 un-
treated AML patients (supplemental data) were quantita-
tively measured based on the gated CD34CD38 cell
population by flow cytometry analysis. It is noteworthy
that MPO expression was significantly higher in
CD34CD38 cells obtained from MPO-high AML cases
than CD34CD38 cells obtained from the MPO-low AML
cases and normal bone marrow CD34 cells (Fig. 6A, top,
middle, and bottom left). The proportion of the MPO-
positive CD34CD38 cells in the MPO-high AML sample
(80.2  5.5%) was significantly higher than that in the
MPO-low AML sample (3.6  1.0%, P  0.001) and the
normal bone marrow CD34 cells (3.1  1.7%, P  0.001)
(Fig. 6A, bottom right). The extent of apoptosis in
CD34CD38 leukemia cells induced by PTL treatment
was also significantly greater in MPO-high AML cases
(87.3  2.7%) compared with the MPO-low AML cases
(32.5  6.4%, P  0.01) and the normal bone marrow
CD34 cells (26.0  11.5%, P  0.01) (Fig. 6B).
NOD/SCID Human Leukemia Mice Model. The NOD/
SCID human leukemia mice model was used to further eval-
uate PTL-induced ablation of leukemia stem cells in relation
to MPO expression. Primary leukemia cells were obtained
from MPO-high AML and MPO-low AML cases, whereas
CD34-positive bone marrow cells were obtained from healthy
donors. These cells were preincubated with 10 	M PTL for
24 h and transplanted into sublethally irradiated NOD/SCID
mice. After 6 to 8 weeks, bone marrow cells were harvested
and labeled with anti-human CD45 antibody to determine
the percentage of human cells that were engrafted in each
animal. As shown in Fig. 6C, PTL treatment significantly
reduced the engraftment ability of primary leukemia cells
that were harvested from the MPO-high AML cases com-
pared with untreated MPO-high AML control cells. However,
the engraftment potential of the PTL-treated primary leuke-
mic blasts from the MPO-low AML cases was not decreased
compared with the untreated control cells. The engraftment
potential of normal CD34 bone marrow cells did not change
with PTL treatment in the NOD/SCID human leukemia mice
model (Fig. 6C). As a whole, these results suggest that PTL is
able to ablate the MPO-expressing AML bulk and LSC while
sparing the normal functioning CD34 hematopoietic pro-
genitor cells.
Discussion
PTL can be considered an attractive antileukemic agent, as
it effectively eradicates AML cells and AML LSC in vitro
while sparing normal hematopoietic stem cells (Guzman et
al., 2005). In this study, we found the expression of MPO to
be a crucial determinant of sensitivity to PTL-induced cell
death in both myeloid leukemia cells and CD34CD38 LSC
candidates. The susceptibility of leukemia cells to PTL-in-
duced apoptosis was significantly higher in the MPO-high
leukemia cells and in the CD34CD38 LSC obtained from
MPO-high AML cases. The results also demonstrated that
PTL does not affect the survival of the CD34 normal bone
marrow cells when used at a concentration that induces a
substantial degree of apoptosis in the MPO-high leukemia
cells. These findings suggest that PTL treatment may be a
promising targeted therapy for MPO-high AML.
It was shown that PTL-mediated anticancer effects may be
related to increased generation of ROS in cancer cells (Kwok
Fig. 3. Alterations in the level of anti- or proapoptotic molecules with
PTL treatment. A and B, top, MPO-low U937 and MPO-high HL60 cells
were treated with 10 	M PTL for 24 h, after which Western blot analysis
was conducted using the appropriate antibodies. B, bottom, cells were
exposed to PTL for 24 h with or without prior incubation with JNK
inhibitor SP600125 or p38 inhibitor SB203580 for 3 h, and then the
percentage of apoptotic cells was determined by flow cytometry. Columns,
mean of three independent experiments; Bars, S.D.
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Fig. 4. Induced overexpression of MPO enhanced sensitivity to PTL-induced apoptosis. K562 cells were transfected with wild-type MPO (K562/MPO),
mutant MPO (K562/R569W), and pCI empty control (K562/Control) cDNA construct using nucleofection as described under Materials and Methods.
After electroporation, stable transfectant clones were selected and used for further experiments. A, heavy () subunit and precursor MPO protein
expression in each transfected cell lines were evaluated using flow cytometry (left) andWestern blot analysis (right). b1, each transfectant was exposed
to the indicated concentration of PTL for 24 h, and then the percentage of apoptotic cells was determined by flow cytometry. The histograms (b2, left)
and bar graphs (b2, right) show the percentage of sub-G1 populations measured by flow cytometry in K562 and K562/MPO cells 24 h after treatment
with 10 	M PTL. The disruption of mitochondrial membrane potential (m) was measured by DiOC6 incubation and flow cytometry analysis (b3,
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et al., 2001; Wen et al., 2002; Wang et al., 2006; Pajak et al.,
2008). ROS induces apoptosis in a variety of cancer cells by
stimulating proapoptotic signaling molecules, activating the
p53 protein pathway, or initiating the mitochondrial apopto-
sis pathway (Wen et al., 2002; Zhang et al., 2004a,b) in a
GSH-sensitive manner (Zhang et al., 2004b; Pajak et al.,
2008). Therefore, the identification and attenuation of mole-
cules that control the generation of ROS in leukemia cells
could enhance their susceptibility to PTL-induced apoptosis.
In this study, we demonstrated that PTL remarkably in-
duces the generation of ROS and apoptosis specifically in
both MPO-high leukemia cell lines and MPO-high primary
leukemic cells obtained from AML patients. However, PTL
failed to generate ROS or induce apoptosis in MPO-low leu-
kemia cells. Pretreatment of leukemia cells with NAC abro-
gated PTL-induced ROS generation, GSH depletion, and cell
death only in the MPO-high cells, suggesting that the gener-
ation of oxidant species is associated with PTL-induced cell
death in the MPO-high leukemia cells. The MPO-specific
inhibitor ABAH and the heme biosynthesis inhibitor ScAc
also significantly inhibited PTL-induced apoptosis in MPO-
high NB4 cells, whereas these MPO inhibitors did not affect
PTL-induced apoptosis in MPO-low U937 cells. MPO silenc-
ing with MPO-specific siRNA transfection significantly de-
creased the level of PTL-induced apoptosis only in MPO-high
NB4 cells in a dose-dependent manner. Furthermore, an
induced overexpression of wild-type MPO gene in K562 cells
led to a significant increase in the PTL-induced ROS gener-
ation, glutathione depletion, activation of caspase cascades,
and mitochondrial pathway-mediated cell death compared
with the overexpression in parental K562 cells. These find-
ings clearly indicate that PTL-induced ROS generation and
apoptosis are critically associated with MPO expression in
leukemia cells.
The specific ROS responsible for PTL-induced apoptosis in
MPO-high leukemia cells was not investigated in this study.
MPO is an endogenous lysosomal enzyme that removes H2O2
and catalyzes the formation of toxic hypochlorous acid
(HOCl) (Hampton et al., 1998; Klebanoff, 2005; Sawayama et
al., 2008). HOCl interacts with other small molecules to
produce various ROS, including hydroxyl radicals (OH), sin-
glet oxygen (1O2), peroxynitrite (ONOO
), and ozone (O3)
(Hampton et al., 1998). Previous studies have demonstrated
that MPO-derived chlorinated oxidants and OH play key
roles in inducing oxidative stress-mediated apoptosis in my-
eloid leukemia cells that are treated with EGCG (Nakazato
et al., 2007), with ROS responsible for triggering apoptosis. It
was suggested that H2O2 produced in the presence of PTL is
converted to HOCl by MPO. However, HOCl was not found to
be responsible for directly inducing apoptosis as MPO-in-
duced apoptosis was blocked by an O2
. scavenger and an OH
scavenger in MPO-positive leukemia cells (Nakazato et al.,
2007). It can be suggested that a reaction between HOCl with
O2
. may result in the formation of a hydroxy radical that could
directly induce apoptosis of MPO-positive leukemia cells.
NF-B is a transcription factor that plays a key role in
regulating cell proliferation, apoptosis, stress responses, and
cell signaling pathways (Hayden and Ghosh, 2008; Baud and
Karin, 2009). It was shown that PTL potentially inhibits
NF-B activity by inhibiting IB kinase complex, resulting in
sustained cytoplasmic retention of NF-B (Bork et al., 1997;
Suvannasankha et al., 2008). Because NF-B is aberrantly
activated in the CD34CD38 LSC population and is asso-
ciated with resistance to chemotherapy in AML (Guzman et
left), and the cytoplasmic translocation of cytochrome c and Smac/DIABLO protein examined by Western blot analysis (b3, right). The cleavage of
caspases-8, -9, -3, and PARP was examined in two cell lines 24 h after PTL treatment using Western blot analysis (b4, left). K562 and K562/MPO cells
were exposed to 10 	M PTL for 24 h in the presence or absence of the caspase inhibitor z-VAD-fmk, after which the percentage of apoptotic cells was
determined by flow cytometry (b4, right). K562 and K562/MPO cells were cultured with 10 	M PTL for 5 h in the presence or absence of prior
incubation with 1 mMNAC, after which intracellular ROS generation (C, top and bottom) and GSH depletion (D) were measured using flow cytometry.
E, K562 and K562/MPO cells were treated with 10 	M PTL for 24 h, and then Western blot analysis was conducted using the appropriate antibodies.
Columns, mean of three independent experiments; Bars, S.D. , P  0.05; , P  0.01.
TABLE 1
PTL-induced apoptosis of primary AML cells and normal CD34-positive bone marrow cells according to MPO expression





1 F/39 M1 18.4 0.3 3.5
2 M/39 M4 9.7 0.4 1.1
3 M/31 M2 4.1 0.8 0.1
4 M/69 M2 6.6 0.7 1.0
5 M/28 M2 48.2 0.6 44.2
6 F/33 M0 59.9 0.7 45.2
7 F/59 M1 66.0 0.1 45.6
8 M/65 M1 46.0 0.7 42.3
9 M/53 M4 46.7 0.8 43.0
10 F/25 M4 70.5 0.1 46.6
Healthy donors
11 M/46 3.7 2.1 9.3
12 M/53 8.8 5.6 7.1
13 F/49 1.0 3.4 8.9
14 F/54 0.1 3.4 9.5
* MPO(%), percentage of MPO-positive cells in the total mononuclear cells.
** After treatment of primary AML cells or normal CD34-positive bone marrow cells with 10 	M PTL for 24 h, the proportion of apoptotic cells was evaluated using flow
cytometry.
*** Control, DMSO.
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al., 2001), it is possible that PTL could be used as an agent to
preferentially eradicate LSC. However, we found that PTL
inhibits NF-B only in the MPO-high leukemia cells. Like-
wise, PTL-induced down-regulation of a variety of NF-B-
regulated antiapoptotic molecules, such as Bcl-xL, Mcl-1, the
XIAP, and survivin (Khoshnan et al., 2000; Taguchi et al.,
2006), were documented only in the MPO-high leukemia
cells. PTL-induced truncation of the BH3-only protein Bid
(tBID) and induction of the proapoptotic targets PUMA and
Bak as well as phosphorylation of p-JNK were also observed
selectively in the MPO-high leukemia cells.
LSC usually exists in a quiescent state and is therefore
unlikely to respond to standard antileukemia chemothera-
peutic agents that preferentially eradicate actively cycling
cells (Holyoake et al., 1999; Graham et al., 2002; Guan et al.,
2003; Guzman et al., 2005). The persistence of LSC after
chemotherapy may be a major factor contributing to relapse
(Jordan and Guzman, 2004; van Rhenen et al., 2005). For
these reasons, development of novel therapeutic agents that
specifically target the LSC population without affecting nor-
mal hematopoietic stem cells is therefore crucial (Guzman et
al., 2005). Because NF-B is constitutively activated in the
LSC population (Guzman et al., 2001), PTL can be considered
a LSC-specific therapeutic agent. These primitive AML cells
may be more sensitive to changes in oxidative stress than
normal hematopoietic stem cells, and the resultant increase
in ROS may contribute to AML-specific cell death (Guzman
et al., 2005). As MPOwas considered a crucial determinant of
PTL-induced apoptosis in leukemia cells, we evaluated MPO
expression in the primary AML cells with respect to CD34
and CD38 antigen coexpression. MPO was highly expressed
in the CD34CD38 leukemia cells obtained from the MPO-
Fig. 5. Differential sensitivity of primary AML cells to PTL-induced apoptosis according to MPO expression. A, constitutive MPO activity of primary
leukemia cells obtained from MPO-high(hi) AML (n  6), MPO-low(lo) AML (n  4) cases as well as CD34-positive normal bone marrow cells (n  4)
was measured using human MPO enzyme immunometric assay. Primary MPO-high and MPO-low AML cases were arbitrarily defined according to
the fraction of leukemic blasts expressing MPO as described underMaterials and Methods. B–D, primary MPO-high AML cells, MPO-low AML cells,
and CD34-positive normal bone marrow cells were treated with 10 	M PTL for 24 h, and then the fraction of apoptotic cells (B) and intracellular ROS
generation (C) were evaluated by flow cytometry (top and bottom), and GSH depletion (D) was examined using luminescence spectrometer. Columns,
mean of three independent experiments; Bars, S.D.
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high AML cases. In contrast, MPO expression was very low
in the CD34CD38 leukemia cells obtained from MPO-low
AML cases. PTL-induced apoptosis of CD34CD38 LSC
candidates was significantly higher in MPO-high AML com-
pared with MPO-low AML cases. This finding suggests that
PTL has a selective effect on MPO-high CD34CD38 LSC.
PTL-induced apoptosis was negligible in the CD34 normal
bone marrow cells in which MPO expression was very low.
Taken together, MPO molecule is demonstrated to be func-
tionally related to PTL-induced apoptosis, ROS generation,
GSH depletion, and the down-regulation of various antiapop-
totic molecules, such as NF-B in leukemia cells and
CD34CD38 LSC candidates. Therefore, the level of MPO
expression within AML cells may be a potential marker for
predicting the sensitivity of leukemia cells and LSC to PTL-
induced cell death. Our findings indicate that PTL treatment
can potentially be considered as a promising targeted ther-
apy for leukemia bulk and LSC in MPO-high AML cells. In
addition, as conventional chemotherapeutic agents may in-
duce NF-B activation in leukemia cells, PTL can be com-
bined with several common antileukemia drugs to overcome
chemoresistance and enhance therapeutic responses.
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